![]() |
市場調查報告書
商品編碼
1832092
2025 年至 2033 年醫用迴旋加速器市場規模、佔有率、趨勢和預測(按類型、產品類型、最終用戶和地區)Medical Cyclotron Market Size, Share, Trends and Forecast by Type, Product Type, End User, and Region, 2025-2033 |
2024年,全球醫用迴旋加速器市場規模為2.475億美元。展望未來, IMARC Group估計,到2033年,市場規模將達到4.783億美元,2025-2033年期間的複合年成長率為7.22%。 2024年,亞太地區佔據了市場主導地位。癌症盛行率的上升、放射性藥物的進步、對正子斷層掃描 (PET) 掃描的需求不斷成長、技術創新、醫療保健基礎設施的擴大、研究活動的增加以及政府推動核醫學和診斷成像的支持性舉措,是影響醫用迴旋加速器市場佔有率的一些關鍵因素。
由於多種關鍵因素,醫療迴旋加速器市場正穩步成長。其中一個主要促進因素是對診斷影像程序的需求不斷成長,尤其是正子斷層掃描 (PET) 掃描,該掃描需要迴旋加速器產生的放射性同位素。全球癌症和心血管疾病發生率的上升進一步擴大了對早期準確診斷工具的需求。放射性藥物和成像技術的進步提高了診斷的效率和準確性,鼓勵更廣泛地採用迴旋加速器系統。此外,新興經濟體醫療基礎設施的不斷擴大以及對核子醫學投資的增加也支持了醫療迴旋加速器市場的成長。政府的支持性政策,包括對癌症診斷的資助以及醫療創新的公私合作,也正在發揮作用。此外,分散式同位素生產的轉變以及診斷中心數量的增加,也增強了對緊湊型、醫院用迴旋加速器的需求。
美國食品藥物管理局 (FDA) 認證使用緊湊型迴旋加速器系統在內部生產鎵-68,使醫院和放射性藥房能夠在本地生產高活度診斷同位素。這項進展有助於更廣泛地獲取 PET 顯影劑,減少對集中供應的依賴,並凸顯了美國市場日益朝向分散式放射性藥物生產的趨勢。例如,2025 年 4 月,Telix ARTMS, Inc. 宣布,Gozellix 成為首個獲得美國食品藥品監督管理局 (FDA) 認證的產品,可參考藥品主文件 (DMF),使用 Telix ARTMS, Inc. 的 QUANTM 輻照系統迴旋加速器技術生產鎵-68。獲得此項批准後,放射性藥局和醫院將能夠利用 ARTMS 的 QIS 迴旋加速器技術和相關靶材,產生 Gozellix 的多居里 68Ga。
癌症和慢性病發生率上升
推動市場發展的主要趨勢之一是全球癌症和其他慢性疾病發生率的上升。癌症仍然是全球主要死因之一,因此需要先進的診斷工具進行早期發現和治療。 2022年,全球癌症死亡人數達970萬,癌症確診人數達5350萬。醫用迴旋加速器在生產用於正子斷層掃描(PET)的放射性同位素方面發揮著至關重要的作用,而PET掃描在早期檢測各種癌症方面非常有效。此外,心血管疾病(CVD)和神經系統疾病等慢性疾病的盛行率不斷上升,也增加了對精準診斷影像技術的需求。隨著醫療保健系統強調早期診斷和有效的治療方案,對可靠、高品質放射性同位素的需求正在推動醫用迴旋加速器市場的成長。
放射性藥物的進展
根據醫用迴旋加速器市場前景,放射性藥物在核醫的診斷和治療中發揮著至關重要的作用。最近的進展導致了更精確和更有針對性的放射性藥物的開發,提高了診斷成像和治療的準確性和有效性。放射性藥物的這項創新擴大了其應用範圍,使得診斷和治療腫瘤學以外的更廣泛疾病成為可能,包括心臟病學和神經病學。因此,根據IMARC Group的報告,2024 年全球放射性藥物市場規模達到 58 億美元。預計到 2033 年,該市場將達到 89 億美元,在 2025-2033 年期間的複合年成長率為 4.9%。此外,人工智慧和機器學習 (ML) 在放射性藥物研究中的結合刺激了新化合物的開發,改善了患者的治療效果。這些進步使得生產新型放射性同位素成為必要,從而推動了醫用迴旋加速器市場規模的成長。
擴大醫療保健基礎設施和診斷影像投資
醫療迴旋加速器市場預測表明,醫療保健基礎設施的擴張對市場成長做出了巨大貢獻。例如,根據印度衛生和家庭福利部的數據,截至 2023 年 3 月,印度共有 1,69,615 個分中心 (SC)、31,882 個初級衛生中心 (PHC)、6,359 個社區衛生中心 (CHC)、1,340 個分區/地區醫院 (SDH)、714 家農村地區醫學院 (362) 家地區服務所 (362) 和農村地區醫學院服務。公營和私營部門組織都在大力投資開發配備創新診斷影像技術的尖端醫療設施。醫院和診斷診所中 PET 和 PET-CT 中心的不斷發展有助於市場成長。此外,政府積極的舉措和對核醫學和診斷成像的支持也進一步促進了市場成長。例如,許多國家正在製定政策,以增強先進診斷設備和關鍵放射性藥物的可及性。這對醫用迴旋加速器市場的前景產生了有利影響,因為它們對於生產此類先進成像程序所需的放射性同位素至關重要。
The global medical cyclotron market size was valued at USD 247.5 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 478.3 Million by 2033, exhibiting a CAGR of 7.22% during 2025-2033. Asia Pacific dominated the market in 2024. The increasing cancer prevalence, advancements in radiopharmaceuticals, rising demand for positron emission tomography (PET) scans, technological innovations, expanding healthcare infrastructure, growing research activities, and supportive government initiatives promoting nuclear medicine and diagnostic imaging are some of the key factors contributing to the medical cyclotron market share.
The market is growing steadily due to several key factors. One major driver is the increasing demand for diagnostic imaging procedures, particularly Positron Emission Tomography (PET) scans, which require radioisotopes produced by cyclotrons. The rising global incidence of cancer and cardiovascular diseases has further amplified the need for early and accurate diagnostic tools. Technological advancements in radiopharmaceuticals and imaging techniques have improved the efficiency and precision of diagnosis, encouraging greater adoption of cyclotron systems. Additionally, expanding healthcare infrastructure in emerging economies and rising investments in nuclear medicine support medical cyclotron market growth. Supportive government policies, including funding for cancer diagnostics and public-private partnerships in healthcare innovation, are also playing a role. Moreover, the shift toward decentralized isotope production and the increasing number of diagnostic centers have strengthened the demand for compact, hospital-based cyclotrons.
FDA certification for in-house gallium-68 production using compact cyclotron systems is enabling hospitals and radiopharmacies to locally manufacture diagnostic isotopes in high activity. This development supports wider access to PET imaging agents, reduces dependence on centralized supply, and underscores a growing move toward decentralized radiopharmaceutical manufacturing in the US market. For instance, in April 2025, Telix ARTMS, Inc. announced that Gozellix became the first product certified by the US Food and Drug Administration (FDA) to reference the drug master file (DMF) for gallium-68 production using Telix ARTMS, Inc.'s QUANTM Irradiation System cyclotron technology. With this approval, radiopharmacies and hospitals would be able to generate multi-Curies of 68Ga for use with Gozellix by utilizing ARTMS' QIS cyclotron technology and related targets.
Rising Prevalence of Cancer and Chronic Diseases
One of the primary trends driving the market is the increasing incidence of cancer and other chronic diseases worldwide. Cancer remains one of the leading causes of death globally, necessitating advanced diagnostic tools for early detection and treatment. In 2022, there were 9.7 million deaths due to cancer, and 53.5 million people living with a cancer diagnosis. Medical cyclotrons play a crucial role in producing radioisotopes used in PET scans, which are highly effective in detecting various types of cancers at an early stage. Additionally, the escalating prevalence of chronic diseases such as cardiovascular disorders (CVD) and neurological conditions has increased the demand for precise diagnostic imaging techniques. As healthcare systems emphasize early diagnosis and effective treatment plans, the need for reliable and high-quality radioisotopes is bolstering the medical cyclotron market growth.
Advancements in Radiopharmaceuticals
Based on the medical cyclotron market outlook, Radiopharmaceuticals play a crucial role in nuclear medicine for both diagnostic and therapeutic purposes. Recent advancements have led to the development of more precise and targeted radiopharmaceuticals, enhancing the accuracy and effectiveness of diagnostic imaging and treatments. This innovation in radiopharmaceuticals has expanded their application scope, enabling the diagnosis and treatment of a broader range of diseases beyond oncology, including cardiology and neurology. As a result, in 2024, the global radiopharmaceuticals market reached USD 5.8 Billion, as per a report by the IMARC Group. The market is further projected to reach USD 8.9 Billion by 2033, growing at a CAGR of 4.9% during 2025-2033. Moreover, the integration of AI and machine learning (ML) in radiopharmaceutical research has spurred the development of new compounds, improving patient outcomes. These advancements necessitate the production of novel radioisotopes, thereby providing an impetus to the medical cyclotron market size.
Expanding Healthcare Infrastructure and Investments in Diagnostic Imaging
The medical cyclotron market forecast indicates that the expansion of healthcare infrastructure significantly contributes to the market growth. For instance, in India, there are a total of 1,69,615 Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District Hospitals (DHs), and 362 Medical Colleges (MCs) serving both rural and urban areas as of March 2023, according to the Ministry of Health and Family Welfare. Both public and private sector organizations are making huge investments in the development of cutting-edge medical facilities equipped with innovative diagnostic imaging technologies. The rising development of PET and PET-CT centers in hospitals and diagnostic clinics is helping in market growth. Additionally, positive government initiatives and funding to support nuclear medicine and diagnostic imaging are further enhancing the market growth. For example, many nations are putting in place policies that enhance access to advanced diagnostic equipment and the availability of critical radiopharmaceuticals. This is having a favorable influence on the outlook of the medical cyclotron market since they are critical in the production of radioisotopes necessary for use in such advanced imaging procedures.
As per the medical cyclotron market research report, the ring cyclotron stood as the largest component in 2024. As per the medical cyclotron industry statistics, ring cyclotrons dominate the market due to their superior capabilities in producing high-energy radioisotopes essential for advanced diagnostic imaging techniques like PET. Their design allows for continuous and efficient acceleration of particles, resulting in higher yields of radioisotopes with greater purity and consistency. Ring cyclotrons are well-suited for large-scale production in medical facilities owing to their efficiency, which guarantees a consistent supply of essential radiopharmaceuticals. Additionally, their advanced technology supports a wider range of isotopes, catering to diverse medical applications beyond oncology, such as cardiology and neurology. The combination of high production capacity, reliability, and versatility positions ring cyclotrons as the preferred choice in the medical cyclotron market.
Cyclotron 16-18 MeV led the market in 2024. The demand for cyclotrons with 16-18 MeV energy levels is mainly driven by their optimal balance between production capacity and operational efficiency. Fluorine-18, which is essential for PET imaging, is among the many radioisotopes that can be produced by these cyclotrons. The 16-18 MeV energy range allows for efficient production of high-purity isotopes with sufficient yield to meet the demands of both large hospitals and commercial radio pharmacies. Additionally, these cyclotrons are cost-effective, offering a favorable return on investment for medical facilities. Their versatility, combined with the ability to support diverse diagnostic and therapeutic applications, makes 16-18 MeV cyclotrons the preferred choice in the industry.
Hospitals led the market in 2024. Medical cyclotron market insights exhibit hospitals as the biggest end users, with their critical role in providing advanced diagnostic and therapeutic services. Medical cyclotrons in hospitals produce essential radioisotopes used in PET and SPECT imaging, which are pivotal for diagnosing and monitoring various diseases, including cancer, CVDs, and neurological disorders. The integration of cyclotrons within hospital settings ensures a timely and reliable supply of these radiopharmaceuticals, enhancing patient care and treatment outcomes. Furthermore, the growing trend of in-house production of radioisotopes allows hospitals to reduce dependence on external suppliers, lower operational costs, and improve the efficiency of their nuclear medicine departments.
In 2024, Asia Pacific accounted for the largest market share. Medical cyclotron market analysis revealed Asia Pacific as the leading region due to robust healthcare infrastructure expansion, particularly in countries like China, Japan, and India, which boosts the demand for advanced diagnostic and therapeutic technologies. Increasing government investments and favorable policies support the adoption of medical cyclotrons in healthcare facilities. Additionally, the rising prevalence of cancer and other chronic diseases in the region amplifies the need for advanced imaging and treatment solutions, further driving market growth. The presence of leading cyclotron manufacturers and growing research and development (R&D) activities in nuclear medicine also contribute to the region's dominance.
United States Medical Cyclotron Market Analysis
The United States medical cyclotron market is primarily driven by the growing demand for advanced diagnostic imaging, particularly positron emission tomography (PET) scans used in oncology, cardiology, and neurology. The increasing incidence of cancer and chronic diseases has heightened the need for reliable radioisotope production, notably Fluorine-18, which is widely used in PET imaging. For instance, the National Cancer Institute estimates that there will be 2,041,910 new cases of cancer in 2025 and approximately 618,120 deaths due to cancer. With many traditional nuclear reactors being phased out or operating under strict regulations, medical cyclotrons provide a safer, decentralized alternative for isotope generation. Moreover, advancements in compact and automated cyclotron technologies have improved operational efficiency and reduced the infrastructure burden, enabling adoption even in mid-sized hospitals and diagnostic centers. The increasing demand for personalized medicine has further strengthened the role of on-site cyclotron production. Government investments, favorable reimbursement policies for PET procedures, and growing partnerships between public institutions and private firms are also propelling industry expansion. Additionally, FDA approvals for new radiopharmaceuticals and a focus on increasing domestic isotope production to reduce import reliance are expanding installations. The trend of integrating cyclotrons with radiochemistry labs for streamlined operations is also attracting attention from healthcare providers seeking to enhance service offerings and reduce lead times in isotope availability, particularly for time-sensitive radiotracers.
Asia Pacific Medical Cyclotron Market Analysis
The Asia Pacific medical cyclotron market is expanding due to increasing government support for indigenizing isotope production and strengthening national nuclear medicine programs. Several countries in the region are enhancing regulatory frameworks and offering funding incentives to encourage hospitals and academic centers to establish cyclotron facilities. Government initiatives to strengthen diagnostic capabilities, along with rising public and private healthcare expenditure, are facilitating cyclotron installations in both urban and tier-2 cities. For instance, from 2017-18 to 2023-24, expenditure on healthcare in India increased from 1.4% to 1.9%, as per the Press Information Bureau (PIB). Additionally, efforts to integrate cyclotron technology with automated radiopharmacy units are improving workflow efficiency and compliance with international safety standards. Local manufacturing of cyclotron components and turnkey radiopharmacy solutions is also gaining traction, lowering installation and maintenance costs. Academic research on novel radiotracers for diseases prevalent in Asia is further boosting demand for dedicated cyclotron facilities tailored to regional diagnostic priorities, facilitating industry expansion.
Europe Medical Cyclotron Market Analysis
The Europe medical cyclotron market is experiencing robust growth, fueled by the rising demand for radioisotopes in PET and SPECT imaging, driven by the increasing geriatric population and the growing prevalence of cancer, cardiovascular, and neurological diseases in the region. According to reports, cancer was the second leading cause of death in the European Union in 2021, with 1.1 Million deaths, which equated to 21.6% of the total number of deaths in the region. Additionally, male mortality rates from cancer were higher at 23.8% than female mortality rates at 19.4%. A strong emphasis on early and precise diagnosis is also prompting hospitals and diagnostic centers across Europe to invest in medical cyclotrons for in-house radiotracer production. Stringent regulatory frameworks around nuclear reactors and radioactive material are further leading to a shift toward decentralized, hospital-based cyclotron installations to ensure a stable and timely isotope supply. Moreover, the European Commission's initiatives to reduce dependency on imported medical isotopes and enhance domestic production capabilities are creating significant funding opportunities and research incentives. Technological advancements in compact and energy-efficient cyclotrons have made installations more feasible in smaller clinical settings, expanding the market beyond large academic centers. Other than this, collaborations between public health bodies, research institutions, and private sector players are fostering innovation and infrastructure development.
Latin America Medical Cyclotron Market Analysis
The Latin America medical cyclotron market is significantly influenced by the growing demand for advanced diagnostic imaging in oncology, neurology, and cardiology, along with increasing awareness about nuclear medicine applications. Countries such as Brazil, Mexico, and Argentina are expanding public and private healthcare investments to enhance diagnostic infrastructure, including PET-CT capabilities. According to the International Trade Administration (ITA), Brazil spends 9.47% of its GDP on healthcare, equating to USD 161 Billion and making the country the largest healthcare market in Latin America. Regional efforts to modernize healthcare systems and improve early disease detection are also supporting market growth. Besides this, strategic collaborations with international cyclotron manufacturers are helping reduce costs and improve access to training and operational support in the region, supporting industry expansion.
Middle East and Africa Medical Cyclotron Market Analysis
The Middle East and Africa medical cyclotron market is being increasingly propelled by rising investments in nuclear medicine infrastructure and growing demand for PET imaging in cancer diagnosis and management. Countries such as the UAE, Saudi Arabia, and South Africa are expanding advanced diagnostic services as part of broader healthcare modernization efforts. Moreover, medical tourism growth in Gulf countries and the establishment of specialized cancer treatment centers are further supporting cyclotron adoption. For instance, according to a report by the IMARC Group, the medical tourism market in Saudi Arabia reached USD 1,341.1 Million in 2024 and is expected to grow at a CAGR of 21.80% during 2025-2033. The limited availability of imported isotopes, combined with the need for timely and efficient radiotracer supply, is further driving interest in localized cyclotron facilities and propelling market growth.
The medical cyclotron market is experiencing growth driven by several key developments. Technological advancements have led to the creation of compact, energy-efficient cyclotrons, enhancing accessibility for healthcare facilities. Public-private partnerships and government funding are increasingly common, aiming to mitigate financial barriers and expand access to cyclotron technologies. Research and development efforts are focused on producing novel radioisotopes for diagnostic and therapeutic applications. Among these trends, government initiatives and funding stand out as prevalent practices, facilitating the establishment of cyclotron facilities and promoting nuclear medicine advancements.